Carolina Céspedes-Garro1,2,3, María-Eugenia G Naranjo1,2, Fernanda Rodrigues-Soares2,4, Adrián LLerena1,2, Jorge Duconge2,5, Lazara K Montané-Jaime6, Hilda Roblejo2,7, Humberto Fariñas1, María de Los A Campos8, Ronald Ramírez2,9, Víctor Serrano2,10, Carmen I Villagrán2,11, Eva M Peñas-LLedó1,2. 1. CICAB Clinical Research Centre, Extremadura University Hospital & Medical School, Badajoz, Spain. 2. RIBEF Ibero-American Network of Pharmacogenetics & Pharmacogenomics. 3. Teaching & Research Department, Genetics Section, School of Biology, University of Costa Rica, San José, Costa Rica. 4. Departamento de Biologia Geral, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 5. Pharmaceutical Sciences Department, School of Pharmacy, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico. 6. Pharmacology Unit Department of Paraclinical Sciences, Faculty of Medical Sciences, The University of West Indies, St Augustine, Trinidad & Tobago. 7. Teaching & Research Department, National Center of Medical Genetics, Havana, Cuba. 8. Secretaría Ejecutiva del Consejo de Ministros de Salud de Centroamérica y República Dominicana, Ciudad Merliot, El Salvador. 9. Facultad de Medicina, UNAN Universidad Autónoma Nacional de Nicaragua, León, Nicaragua. 10. CIIMET Centro de Investigación e Información de Medicamentos y Tóxicos, Facultad de Medicina, Universidad de Panamá, Panamá, Panamá. 11. Facultad de Ciencias Médicas, Dirección de Investigación, Universidad de San Carlos de Guatemala, Guatemala.
Abstract
AIM: The present review was aimed at analyzing the pharmacogenetic scientific activity in Central America and the Caribbean. MATERIALS & METHODS: A literature search for pharmacogenetic studies in each country of the region was conducted on three databases using a list of the most relevant pharmacogenetic biomarkers including 'phenotyping probe drugs' for major drug metabolizing enzymes. The review included 132 papers involving 47 biomarkers and 35,079 subjects (11,129 healthy volunteers and 23,950 patients). RESULTS: The country with the most intensive pharmacogenetic research was Costa Rica. The most studied medical therapeutic area was oncology, and the most investigated biomarkers were CYP2D6 and HLA-A/B. Conclusion: Research activity on pharmacogenetics in Central American and the Caribbean populations is limited or absent. Therefore, strategies to promote effective collaborations, and foster interregional initiatives and research efforts among countries from the region could help for the rational clinical implementation of pharmacogenetics and personalized medicine.
AIM: The present review was aimed at analyzing the pharmacogenetic scientific activity in Central America and the Caribbean. MATERIALS & METHODS: A literature search for pharmacogenetic studies in each country of the region was conducted on three databases using a list of the most relevant pharmacogenetic biomarkers including 'phenotyping probe drugs' for major drug metabolizing enzymes. The review included 132 papers involving 47 biomarkers and 35,079 subjects (11,129 healthy volunteers and 23,950 patients). RESULTS: The country with the most intensive pharmacogenetic research was Costa Rica. The most studied medical therapeutic area was oncology, and the most investigated biomarkers were CYP2D6 and HLA-A/B. Conclusion: Research activity on pharmacogenetics in Central American and the Caribbean populations is limited or absent. Therefore, strategies to promote effective collaborations, and foster interregional initiatives and research efforts among countries from the region could help for the rational clinical implementation of pharmacogenetics and personalized medicine.
Entities:
Keywords:
Caribbean region; Central America; biomarkers; pharmacogenetics; pharmacogenomics
Authors: A I Morales; B Morera; G Jiménez-Arce; G Sánchez-Rivera; F Calafell; R Barrantes Journal: Forensic Sci Int Date: 2001-12-15 Impact factor: 2.395
Authors: Michie Hisada; Renu B Lal; Silvina Masciotra; Donna L Rudolph; Maureen P Martin; Mary Carrington; Rainford J Wilks; Angela Manns Journal: J Infect Dis Date: 2002-04-16 Impact factor: 5.226
Authors: Stephanie J Weinstein; Gloria Gridley; Lea C Harty; Scott R Diehl; Linda M Brown; Deborah M Winn; Eleuterio Bravo-Otero; Richard B Hayes Journal: J Nutr Date: 2002-04 Impact factor: 4.798
Authors: S S Wang; C M Wheeler; A Hildesheim; M Schiffman; R Herrero; M C Bratti; M E Sherman; M Alfaro; M L Hutchinson; J Morales; A Lorincz; R D Burk; M Carrington; H A Erlich; R J Apple Journal: J Infect Dis Date: 2001-10-29 Impact factor: 5.226
Authors: Fernando de Andrés; Catalina Altamirano-Tinoco; Ronald Ramírez-Roa; Carlos F Montes-Mondragón; Pedro Dorado; Eva M Peñas-Lledó; Adrián LLerena Journal: Pharmacogenomics J Date: 2020-10-06 Impact factor: 3.550